Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation-Reference-Cited by-同舟云学术

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation

Published:2018-03-24 Issue:5 Volume:9 Page:656-661
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Xia Pinghui¹,Cao Jinlin¹,Lv Xiayi¹,Wang Luming¹,Lv Wang¹,Hu Jian¹^ORCID

Affiliation:

1. Department of Thoracic Surgery; The First Affiliated Hospital, Zhejiang University School of Medicine; Hangzhou China

Funder

The Key Project of Zhejiang Province Science and Technology Plan, China

The National Key Research and Development Program of China

Key Project of Zhejiang Province Science, Technology Plan12,China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12624/fullpdf

Reference31 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Novel targets in non-small cell lung cancer: ROS1 and RET fusions;Gainor;Oncologist,2013

3. Lung cancer incidence trends by histology type among Asian American, Native Hawaiian, and Pacific Islander populations in the United States, 1990-2010;Cheng;Cancer Epidemiol Biomarkers Prev,2014

4. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in mainland China;Wu;J Thorac Oncol,2007

5. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer;Cancer Medicine;2022-09-09

2. Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma Patient With Kras Mutation After Osimertinib Resistance;American Journal of Therapeutics;2021-07-08

3. Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non‐small cell lung cancer patients;British Journal of Clinical Pharmacology;2020-11-15

4. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself;Angiogenesis;2020-04-24

5. Icotinib/rivoceranib;Reactions Weekly;2018-06